Skip to content
Cococin
  • About Cococin
  • IP Rights
    • Patents
  • About Sabinsa
    • Newsroom
      • Press Release
      • White Papers
      • Ads
      • Videos
      • FAQ’s
  • Contact Us

Study Utilizing Sabinsa’s Materials Determined Superiority of Pterostilbene Over Resveratrol in Reducing Blood Glucose Levels and Restoring Muscle Health in Diabetic Rats

In research recently published in Evidence-Based Complementary and Evidence Based Medicine, https://doi.org/10.1155/2018/9012352, researchers from Turkey investigated the effects of Pterostilbene, provided by Sabinsa, in experimental diabetes in animals. The researchers found that Pterostilbene not only controlled the weight loss observed in diabetic animals, it was effective in reducing blood glucose levels and also in increasing serum insulin levels. The antioxidant activity of pterostilbene was confirmed by reduced malondialdehyde levels.

The researchers also compared Pterostilbene vs Resveratrol and noted that Pterostilbene excelled over Resveratrol in almost all major parameters, which they attributed to its superior bioavailability and activity.

Diabetes is known to cause damage to structure, morphology and contractility of skeletal muscles, so that was also investigated. In this research, Pterostilbene was shown to reverse, in a major way, the skeletal infirmities caused by diabetes as judged by the restored values of isometric contraction parameters of gastrocnemius muscle significantly affected by diabetes.

“Diabetes is a highly debilitating disease diagnosed as afflicting nearly 10% of the US population with an equal percentage of undiagnosed, with the total cost of diagnosed diabetes in the US alone amounted $327 billion in 2017, said Nagabhushanam Kalyanam, Ph.D., Sabinsa’s President of Research and Development. “While pharmaceutical treatments continue to evolve to contain the effects of the disease, sedentary lifestyle and unhealthy diets increase the diabetes population. Dietary supplementation is a robust add-on method to control the effects of diabetes without side-effects.”

Sabinsa offers various strengths of Pterostilbene including >99%. It also offers natural Pterostilbene >90% in commercial quantities. Numerous publications covering the various beneficial health aspects of Sabina’s Pterostilbene-containing products, trademarked Silbenol®, have appeared in peer-reviewed literature with this present paper the latest member in the series

Back

About Sabinsa

Sabinsa is a manufacturer, supplier and marketer of herbal extracts, cosmeceuticals, minerals, dietary supplements and specialty fine chemicals for the nutritional, cosmetic, pharmaceutical and food industries.

Read More..

Certificates

KosherIFANCA Halal Certified
Non-GMO

Headquarters

Sabinsa Corporation

20 Lake Drive 

East Windsor

NJ 08520, USA

 

Tel : +1 732 777 1111

Fax: +1 732 777 1443

info@sabinsa.com

Global Contact List

USAIndia
Utah, USAJapan
AustraliaPoland
BrasilKorea
CanadaSouth Africa
ChinaVietnam
Germany 

Contact us

    © 2025 Sabinsa. All Rights Reserved | Privacy Policy | Sitemap | Terms of Use | Disclaimer

    ×

    Disclaimer

    US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

    EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.